Home / Stocks / IQV

IQVIA Holdings (IQV, Life Sciences Tools & Services) Stock Valuation & Fair Value Weak on forward returns

IQVIA Holdings (IQV, Life Sciences Tools & Services) trades at a blended P/E of 20.3, about 7% below its historical normal valuation, with a forward growth estimate of 11.3% and a PEG of 1.79. Analysts' one-year estimates have been hit 73% of the time. Priced at its historical normal P/E of 21.8 on the same blended earnings, the 2026-10-02 close of $258.21 corresponds to about $277 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-10-05
Blended P/E
20.3
Normal P/E
21.8
PEG
1.79
Fwd growth
11.3%
Div yield
0.0%
RSI (14)
46.6
Neutral
Technical context
  • Price $258.88 at the 2026-10-08 close, 2.8% below the 20-day average ($266.29) and 1.0% above the 50-day ($256.42).
  • RSI (14) at 46.6.
  • 52-week range $156.66 to $275.02: the price is 5.9% below the high and 65.2% above the low.

The Street vs SeerForecast

Wall Street's mean price target for IQV is $288.74 across 19 analysts, 11.5% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: weak on forward returns. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from mixed on our tests (2026-06-03) to weak on forward returns (2026-10-05).

Blended P/E and rating by weekBlended P/E moved from 14.7 to 20.3 between 2026-06-03 and 2026-10-02, against a normal P/E of 21.8, with 1 rating change over 37 recorded weeks.2026-06-03: P/E 14.7, Mixed on our tests, recalculated for the week of 2026-06-032026-06-10: P/E 14.9, Mixed on our tests, recalculated for the week of 2026-06-102026-06-12: P/E 14.9, Mixed on our tests, recalculated for the week of 2026-06-142026-06-16: P/E 14.9, Mixed on our tests, recalculated for the week of 2026-06-162026-06-18: P/E 14.9, Mixed on our tests, recalculated for the week of 2026-06-212026-07-02: P/E 16.4, Mixed on our tests, recalculated for the week of 2026-07-022026-07-06: P/E 16.7, Mixed on our tests, recalculated for the week of 2026-07-062026-07-09: P/E 16.7, Mixed on our tests, recalculated for the week of 2026-07-092026-07-10: P/E 16.8, Mixed on our tests, recalculated for the week of 2026-07-122026-07-13: P/E 16.8, Mixed on our tests, recalculated for the week of 2026-07-132026-07-14: P/E 16.8, Mixed on our tests, recalculated for the week of 2026-07-142026-07-20: P/E 16.6, Mixed on our tests, recalculated for the week of 2026-07-202026-07-22: P/E 16.6, Mixed on our tests, recalculated for the week of 2026-07-222026-07-24: P/E 16.7, Mixed on our tests, recalculated for the week of 2026-07-252026-07-27: P/E 16.7, Mixed on our tests, recalculated for the week of 2026-07-272026-07-31: P/E 19.0, Mixed on our tests, recalculated for the week of 2026-07-312026-07-31: P/E 18.8, Mixed on our tests, recorded live 2026-08-032026-08-07: P/E 18.6, Mixed on our tests, recalculated for the week of 2026-08-072026-08-07: P/E 19.1, Mixed on our tests, recorded live 2026-08-102026-08-14: P/E 19.3, Mixed on our tests, recalculated for the week of 2026-08-142026-08-14: P/E 19.3, Mixed on our tests, recorded live 2026-08-172026-08-21: P/E 20.4, Weak on forward returns, recalculated for the week of 2026-08-212026-08-21: P/E 20.7, Weak on forward returns, recorded live 2026-08-242026-08-27: P/E 20.7, Weak on forward returns, recalculated for the week of 2026-08-272026-08-28: P/E 20.8, Weak on forward returns, recalculated for the week of 2026-08-282026-08-28: P/E 20.8, Weak on forward returns, recalculated for the week of 2026-08-302026-08-28: P/E 20.8, Weak on forward returns, recorded live 2026-08-312026-09-04: P/E 21.2, Weak on forward returns, recalculated for the week of 2026-09-052026-09-04: P/E 21.2, Weak on forward returns, recorded live 2026-09-072026-09-11: P/E 20.7, Weak on forward returns, recalculated for the week of 2026-09-122026-09-11: P/E 20.7, Weak on forward returns, recorded live 2026-09-142026-09-18: P/E 21.1, Weak on forward returns, recalculated for the week of 2026-09-192026-09-18: P/E 21.1, Weak on forward returns, recorded live 2026-09-212026-09-25: P/E 21.3, Weak on forward returns, recalculated for the week of 2026-09-262026-09-25: P/E 21.3, Weak on forward returns, recorded live 2026-09-282026-10-02: P/E 20.3, Weak on forward returns, recalculated for the week of 2026-10-032026-10-02: P/E 20.3, Weak on forward returns, recorded live 2026-10-0516.018.020.0Jun 3Jul 3Aug 2Sep 2Oct 2Normal P/E 21.8
Mixed on our testsWeak on forward returns

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-06-03P/E 14.7-32%Mixed on our tests (recalculated)
2026-08-21P/E 20.4-6%Weak on forward returns (recalculated)
2026-09-26P/E 21.3-2%Weak on forward returns (recalculated)
2026-10-05P/E 20.3-7%Weak on forward returns ← now
Show all 37 weeks
WeekBlended P/EPremium to normal P/ERating
2026-06-03P/E 14.7-32%Mixed on our tests (recalculated)
2026-06-10P/E 14.9-32%Mixed on our tests (recalculated)
2026-06-14P/E 14.9-32%Mixed on our tests (recalculated)
2026-06-16P/E 14.9-32%Mixed on our tests (recalculated)
2026-06-21P/E 14.9-32%Mixed on our tests (recalculated)
2026-07-02P/E 16.4-25%Mixed on our tests (recalculated)
2026-07-06P/E 16.7-23%Mixed on our tests (recalculated)
2026-07-09P/E 16.7-23%Mixed on our tests (recalculated)
2026-07-12P/E 16.8-23%Mixed on our tests (recalculated)
2026-07-13P/E 16.8-23%Mixed on our tests (recalculated)
2026-07-14P/E 16.8-23%Mixed on our tests (recalculated)
2026-07-20P/E 16.6-24%Mixed on our tests (recalculated)
2026-07-22P/E 16.6-24%Mixed on our tests (recalculated)
2026-07-25P/E 16.7-23%Mixed on our tests (recalculated)
2026-07-27P/E 16.7-23%Mixed on our tests (recalculated)
2026-07-31P/E 19.0-13%Mixed on our tests (recalculated)
2026-08-03P/E 18.8-14%Mixed on our tests
2026-08-07P/E 18.6-15%Mixed on our tests (recalculated)
2026-08-10P/E 19.1-13%Mixed on our tests
2026-08-14P/E 19.3-12%Mixed on our tests (recalculated)
2026-08-17P/E 19.3-12%Mixed on our tests
2026-08-21P/E 20.4-6%Weak on forward returns (recalculated)
2026-08-24P/E 20.7-5%Weak on forward returns
2026-08-27P/E 20.7-5%Weak on forward returns (recalculated)
2026-08-28P/E 20.8-4%Weak on forward returns (recalculated)
2026-08-30P/E 20.8-5%Weak on forward returns (recalculated)
2026-08-31P/E 20.8-5%Weak on forward returns
2026-09-05P/E 21.2-3%Weak on forward returns (recalculated)
2026-09-07P/E 21.2-3%Weak on forward returns
2026-09-12P/E 20.7-5%Weak on forward returns (recalculated)
2026-09-14P/E 20.7-5%Weak on forward returns
2026-09-19P/E 21.1-3%Weak on forward returns (recalculated)
2026-09-21P/E 21.1-3%Weak on forward returns
2026-09-26P/E 21.3-2%Weak on forward returns (recalculated)
2026-09-28P/E 21.3-2%Weak on forward returns
2026-10-03P/E 20.3-7%Weak on forward returns (recalculated)
2026-10-05P/E 20.3-7%Weak on forward returns ← now

Frequently asked questions

Is IQVIA Holdings stock overvalued?

At a blended P/E of 20.3 versus its historical normal P/E of 21.8, IQVIA Holdings trades about 7% below its typical valuation, with a PEG of 1.79 on 11.3% forward growth. tickerseer currently rates it weak on forward returns.

What is IQVIA Holdings's fair value and PEG?

IQVIA Holdings trades at a blended P/E of 20.3 against a historical normal P/E of 21.8, a PEG of 1.79, and a forward growth estimate of 11.3%. Priced at its historical normal P/E of 21.8 on the same blended earnings, the 2026-10-02 close of $258.21 corresponds to about $277 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of IQVIA Holdings changed?

tickerseer's rating moved from mixed on our tests (2026-06-03) to weak on forward returns (2026-10-05).

What is the analyst price target for IQVIA Holdings?

The mean Wall Street price target for IQVIA Holdings is $288.74 across 19 analysts, 11.5% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Life Sciences Tools & Services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track IQV free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.